PubRank

Sylvie Negrier

Author PubWeight™ 133.51‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 39.39
2 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 30.94
3 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 13.52
4 Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011 12.13
5 Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2009 8.68
6 Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009 6.86
7 Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008 5.27
8 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013 3.79
9 Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 3.65
10 Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012 2.56
11 Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006 1.75
12 Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007 1.37
13 Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005 1.36
14 [Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer 2002 1.24
15 The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 2013 1.01
16 Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol 2012 0.99
17 Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 2004 0.88
18 O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs 2008 0.84
19 Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol 2014 0.82
20 Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLoS One 2009 0.80
21 Diffuse medulla oblongata and pontine gliomas in childhood. A review of 37 cases. Bull Cancer 2004 0.79
22 Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy. Anticancer Res 2012 0.78
23 Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J Cancer Res Ther 2010 0.76
24 [Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site]. Bull Cancer 2003 0.75
25 Sorafenib and sunitinib for elderly patients with renal cell carcinoma. J Geriatr Oncol 2013 0.75